← Back to Search

Virtual Group Speech Therapy for Head and Neck Cancer

Phase 1 & 2
Recruiting
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 6 weeks post radiation
Awards & highlights
No Placebo-Only Group

Summary

This trial will study how a virtual, group-based therapy, with a patient partner, can improve care for head and neck cancer patients.

Who is the study for?
Adults over 18 with head or neck cancer starting chemoradiotherapy for cure can join. They need a radiation dose of at least 60 Grays and must speak French well enough for questionnaires. Those with distant cancer spread, planned total laryngectomy, prior severe swallowing issues, another simultaneous cancer, previous head/neck radiation, or significant cognitive impairments cannot participate.
What is being tested?
The trial is testing the eG2 Intervention: a virtual group speech therapy guided by a patient partner to prevent swallowing difficulties in patients undergoing chemoradiotherapy for head and neck cancers. It aims to improve care quality and accessibility while optimizing healthcare resources.
What are the potential side effects?
Since this intervention involves speech therapy rather than medication, typical drug side effects are not expected. However, participants may experience fatigue from regular sessions or stress from technology use.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 6 weeks post radiation
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 6 weeks post radiation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of nasogastric tube

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: virtual group speech therapy intervention guided by a patient partnerExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
377 Previous Clinical Trials
131,444 Total Patients Enrolled
Université du Québec à Trois-RivièresOTHER
47 Previous Clinical Trials
4,455 Total Patients Enrolled

Media Library

Virtual Group Speech Pathology Intervention Clinical Trial Eligibility Overview. Trial Name: NCT05621889 — Phase 1 & 2
Swallowing Difficulty Research Study Groups: virtual group speech therapy intervention guided by a patient partner
Swallowing Difficulty Clinical Trial 2023: Virtual Group Speech Pathology Intervention Highlights & Side Effects. Trial Name: NCT05621889 — Phase 1 & 2
Virtual Group Speech Pathology Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05621889 — Phase 1 & 2
~4 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top